Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TAK) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
tak · stock forecast · 6 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 6 Wall Street analysts in the past 3 months
Buy
6 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $15.60
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $15.07 | ↓ 3.37% |
1-day model range: $15.03–$15.11. Peak: $15.11 (-3.37%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $17 | +10.8% |
| 2028 | $18 | +18.5% |
| 2029 | $19 | +23.9% |
| 2030 | $20 | +27.6% |
| 2031 | — | +30.0% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · TAK · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-05-16 | TD Cowen | Maintains | Outperform→Outperform |
| 2023-04-04 | TD Cowen | Maintains | Outperform→Outperform |
| 2023-03-16 | B of A Securities | Upgrade ↑ | Neutral→Buy |
| 2022-07-19 | Cowen & Co. | Upgrade ↑ | Market Perform→Outperform |
| 2021-10-07 | Morgan Stanley | Downgrade ↓ | Overweight→Equal Weight |
| 2020-03-11 | JP Morgan | Maintains | Overweight→Overweight |
| 2019-11-01 | Cowen & Co. | Maintains | Market Perform→Perform |
| 2019-09-24 | Jefferies | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Takeda Pharmaceutical Company Limited (TAK) stock. Of the recent 8 rating actions, 2 were upgrades and 1 were downgrades. 6 analysts currently cover TAK.
Analyst Recommendation Trends
TAK analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$4.65T
↓ 3.9% YoY
Revenue Next Year
$4.72T
↑ 1.4% YoY
EPS This Year
$70.05
EPS Next Year
$99.50
↑ 42.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast TAK EPS of $70.05 for the current fiscal year, based on estimates from 2 analysts. The TAK revenue forecast is $4.65T for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The TAK stock forecast is supported by two independent data sources: analyst consensus ratings from 6 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus TAK price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The TAK short-term stock prediction for tomorrow is $15.07 (-3.37%). The TAK stock price prediction for 2027 estimates an average of $17. The TAK stock prediction for 2030 projects a range of $19–$20.
Takeda Pharmaceutical Company Limited trades on NYSE under the ticker TAK. The TAK stock outlook for 2027 is broadly positive, supported by a Buy consensus among 83% of covering analysts.
Frequently asked questions
TAK forecast · 8 questionsAccording to 6 Wall Street analysts, the average 12-month TAK price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $15.60.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.